Management of ascites in patients with end-stage liver disease

Reviews in Gastroenterological Disorders

Volumn 4, Issue 4, 2004, Pages 175-185

  Saadeh, Sherif ^a   Davis, Gary L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abdominal paracentesis; Ascites; Cirrhosis; Diuretics; End stage liver disease; Hepatorenal syndrome; Hernia; Sodium restriction; Spontaneous bacterial peritonitis

Indexed keywords

AMILORIDE; BUMETANIDE; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; FUROSEMIDE; LOOP DIURETIC AGENT; NORFLOXACIN; OFLOXACIN; POTASSIUM SPARING DIURETIC AGENT; SERUM ALBUMIN; SPIRONOLACTONE; TRIAMTERENE;

ABDOMINAL WALL HERNIA; ASCITES; ASCITES FLUID; BACTERIAL PERITONITIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; HEPATORENAL SYNDROME; HUMAN; INFECTION RISK; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; PARACENTESIS; PERITONEAL FLUID; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; RISK ASSESSMENT; SODIUM RESTRICTION; SURVIVAL RATE;

ASCITES; DIAGNOSIS, DIFFERENTIAL; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PERITONEOVENOUS SHUNT; PERITONITIS;

EID: 10944244268     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudates-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215-220.
2. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:12-18.
3. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31:468-475.
4. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
5. Yu AS, Hu KQ. Management of ascites. Clin Liver Dis. 2001;5:541-568.
6. Sherlock S, Shaldon S. The aetiology and management of ascites in patients with hepatic cirrhosis: a review. Gut. 1963;4:95-105.
7. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646-1654.
8. Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: the overflow theory of ascites formation. Ann NY Acad Sci. 1970;70:202-212.
9. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology. 1996; 20:1359-1363.
10. Morales-Ruiz M, Jimenez W, Perez-Sala D, et al. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology. 1996;24:1481-1486.
11. Sogni P, Moreau R, Gadano A, et al. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol. 1995;23:218-224.
12. Runyon BA. AASLD practice guideline: management of adult patients with ascites due to cirrhosis. Hepatology. 2004;39:841-856.
13. Cattau EL Jr, Benjamin SB, Knuff TE, et al. The accuracy of the physical exam in the diagnosis of suspected ascites. JAMA. 1982;247:1164-1166.
14. Reynolds TB. Ascites. Clin Liver Dis. 2000; 4:151-168.
15. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 7th ed. Philadelphia: W.B. Saunders, 2002:1517-1542.
16. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330:337-342.
17. Hoefs JC. Serum protein concentration and portal pressure determine the ascetic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med. 1983;102:260-273.
18. Mauer K, Manzione NC. Usefulness of the serum-ascites albumin gradient in separating transudative from exudative ascites: another look. Dig Dis Sci.1988;33:1208-1212.
19. Pare P, Talbot J, Hoefs JC. Serum-ascites albumin concentration gradient: a physiological approach to the differential diagnosis of ascites. Gastroenterology. 1983;85:240-244.
20. Rector WG, Reynolds TB. Superiority of the serum-ascites albumin difference over the ascites total protein concentration in separation of "transudative" and "exudative" ascites. Am J Med. 1984;77:83-85.
21. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117: 215-220.
22. Akriviadis EA, Runyon BA. The value of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology. 1990;98:127-133.
23. Runyon BA. Amylase levels in ascitic fluid. J Clin Gastroenterol. 1987;9:172-174.
24. Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. Ann Intern Med. 1982;96:358-364.
25. Runyon BA. Ascitic fluid bilirubin concentration as a key to choleperitoneum. J Clin Gastroenterol. 1987;9:543-545.
26. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8:1104-1109.
27. Hillebrand DJ, Runyon BA, Yasmineh WG, et al. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology. 1996;24:1408-1412.
28. De Groen PC, Rakela J, Moore C, et al. Diagnostic laparoscopy in gastroenterology: a 14-year experience. Dig Dis Sci. 1987;32:677-681.
29. Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist. 1995;3:311-328.
30. Pinzello G, Simonetti RG, Craxi A, et al. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic patients. Hepatology. 1983;3:545-549.
31. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology. 1988;95:1351-1355.
32. Runyon BA, Antillon MR, Akriviadis EA, et al. Bedside inoculation of blood culture bottles is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. J Clin Microbiol. 1990;28:2811-2812.
33. Castellote J, Lopez C, Gornals J, et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology 2003; 37:893-896.
34. Runyon BA. Strips and tubes: refining the diagnosis of spontaneous bacterial peritonitis. Hepatology. 2003;37:745-747.
35. Runyon BA. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med. 1986;146:2259-2261.
36. Sakai H, Mendler MH, Runyon BA. The left lower quadrant is the best site for paracentesis: an ultrasound evaluation [abstract]. Hepatology. 2002;36:525A.
37. Webster ST, Brown KL, Lucey MR. Hemorrhagic complications of large volume abdominal paracentesis. Am J Gastroenterol. 996;92:366-368.
38. Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of forosemide vs spironolactone in nonazotemic cirrhosis with ascites. Gastroenterology. 1983; 84:961-968.
39. Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology. 1992;102:1680-1685.
40. Angeli P, Pria MD, De Bei E, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology. 1994;19:72-79.
41. Stanley MM, Ochi S, Lee KK, et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med. 1989;321:1632-1638.
42. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23:164-176.
43. Rossle M, Ochs A, Gulberg, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000;342:1701-1707.
44. Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123:1839-1847.
45. Gines P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med. 1991; 325:829-835.
46. Peltekian KM, Wong F, Liu PP, et al. Cardiovascular, renal and neurohumoral responses to single large-volume paracentesis in cirrhotic patients with diuretic-resistant ascites. Am J Gastroenterol. 1997;92:394-399.
47. Runyon BA. Patient selection is important in studying the impact of large-volume paracentesis on intravascular volume. Am J Gastroenterol. 1997;92:371-373.
48. Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology. 1990;98:146-151.
49. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology. 1987; 93:234-241.
50. Gines P, Tito L, Arroyo V, et al. Randomized study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493-1502.
51. Sanyal AJ, Genning C, Reddy RK, et al. The North American study for the treatment of refractory ascites. Gastroenterology. 2003;124:634-641.
52. Salerno F, Merli M, Cazzaniga M, et al. Randomized controlled study of TIPS vs. paracentesis with albumin in cirrhosis with refractory ascites [abstract]. Hepatology 2002;36:318A.
53. Gerbes AL, Gulberg V, Waggershauser T, et al. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology. 1998;28:683-688.
54. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular portosystemic shunts. Hepatology. 2000;31:864-871.
55. Hoefs JC, Canawati HN, Sapico FL, et al. Spontaneous bacterial peritonitis. Hepatology. 1982;2:399-407.
56. Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology. 1984;4:1209-1211.
57. Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology. 1990;12:710-715.
58. Felisart J, Rimola A, Arroyo V, et al. Randomized comparative study of efficacy and nephrotoxicity of ampicillin plus tobramycin versus cefotaxime in cirrhosis with severe infections. Hepatology. 1985;5:457-462.
59. Runyon BA, Akriviadis EA, Sattler FR, et al. Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis. Dig Dis Sci. 1991;36:1782-1786.
60. Runyon BA, McHutchison JG, Antillon MR, et al. Short-course vs long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled trial of 100 patients. Gastroenterology. 1991;100:1737-1742.
61. Navasa M, Follo A, Llovet JM, et al. Randomized comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology. 1996;111:1011-1017.
62. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999; 341:403-409.
63. Akriviadis EA, McHutchison JG, Runyon BA. Follow-up paracentesis is not usually necessary in patients with typical spontaneous ascitic fluid infection [abstract]. Hepatology. 1997; 26:288A.
64. Bernard B, Grange JD, Khac N, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29:1655-1661.
65. Younossi ZM, McHutchison JG, Ganiats TG. An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. J Hepatol. 1997;27:295-298.
66. Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology. 1992;103:1267-1272.
67. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986;91:1343-1346.
68. Soriano G, Teixedo M, Guarner C, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology. 1991;100:477-481.
69. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12:716-724.
70. Singh N, Gayowski T, Yu VL, et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med. 1995;122:595-598.
71. Gines P, Guevara M. Good news for hepatorenal syndrome. Hepatology. 2002;36:504-506.
72. Forni LG, Hilton PJ. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med. 1997; 336:1303-1309.
73. Angeli P, Volpin R, Gerunda G, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690-1697.
74. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type I hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923-930.
75. Guevara M, Gines P, Bandi C, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998; 28:416-422.
76. Belghiti J, Durand F. Abdominal wall hernias in the setting of cirrhosis. Semin Liver Dis. 1997; 17:219-226.
77. Runyon BA, Juler GL. Natural history of umbilical hernias in patients with and without ascites. Am J Gastroenterol. 1985;80:38-39.